US3803174A - Substituted xanthone carboxylic acid compounds - Google Patents

Substituted xanthone carboxylic acid compounds Download PDF

Info

Publication number
US3803174A
US3803174A US00174259A US17425971A US3803174A US 3803174 A US3803174 A US 3803174A US 00174259 A US00174259 A US 00174259A US 17425971 A US17425971 A US 17425971A US 3803174 A US3803174 A US 3803174A
Authority
US
United States
Prior art keywords
carboxylic acid
xanthone
compounds
reaction
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00174259A
Other languages
English (en)
Inventor
J Pfister
I Harrison
J Fried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US00174259A priority Critical patent/US3803174A/en
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Priority to SE7209195A priority patent/SE387945B/xx
Priority to CH1045572A priority patent/CH591470A5/xx
Priority to CH1030676A priority patent/CH592076A5/xx
Priority to DE19722265051 priority patent/DE2265051A1/de
Priority to DE2234250A priority patent/DE2234250A1/de
Priority to GB3253272A priority patent/GB1398097A/en
Priority to JP6984472A priority patent/JPS5344473B2/ja
Priority to NL7209619A priority patent/NL7209619A/xx
Priority to ES404787A priority patent/ES404787A1/es
Priority to CA146,892A priority patent/CA1012543A/en
Priority to FR7225355A priority patent/FR2150309B1/fr
Priority to US425885A priority patent/US3885038A/en
Application granted granted Critical
Publication of US3803174A publication Critical patent/US3803174A/en
Priority to ES435560A priority patent/ES435560A1/es
Priority to ES435561A priority patent/ES435561A1/es
Priority to HK308/76*UA priority patent/HK30876A/xx
Priority to MY134/76A priority patent/MY7600134A/xx
Priority to JP4631577A priority patent/JPS537675A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones

Definitions

  • the present invention is directed to novel substituted xanthone carboxylic acid compounds useful as intermediates for the preparation of other useful xanthone-Z-carboxylic acid compounds, and to compositions containing and methods utilizing these compounds as the essential ingredient in the treatment of symptoms associated with allergic manifestations, for example, asthmatic conditions.
  • the present invention relates to novel -5 and C-7 mercapto and lower alkylthio substituted xanthone-Z-carboxylic acid compounds selected from those represented by the following formulas:
  • the compounds of the present invention are useful as intermediates for the preparation of other xanthone-Z-carboxylic acid compounds which, in turn, are useful in the treatment of various allergic conditions.
  • the process by which the compounds of the present invention are useful for preparing the other useful xanthone-Z-carboxylic acid compounds is described in our copending application Ser. No. 174,261, filed on even date herewith and entitled Novel Substituted Xanthone Carboxylic Acid Compounds.
  • this process involves treating a 0-5 or C-7 (lower alkylthio)xanthone-2-carboxylic" acid or a lower alkyl ester thereof, of the present invention, and prepared herein from the corresponding (3-5 or 0-7 mercaptoxanthone-2-carboxylic acid compounds, with:
  • a peracid such as peracetic acid and m-chloroperbenzoic, to give the corresponding 0-5 or C-7 lower alkylsulfinylxanthone-Z-carboxylic acid compmuuds;
  • the compounds of the present invention are also useful for relieving symptoms associated with allergic manifestations such as are brought about by antigen-antibody (allergic) reactions.
  • the method employing the compounds hereof serves to inhibit the effects of the allergic reaction when administered in an effective amount. While not intending to be bound by any theoretical mechanism of action, the method hereof is believed to operate by inhibiting the release and/or the action of toxic products, e.g. histamine, 5hydroxytryptamine, slow releasing substance (SRS-A), and others, which are produced as a result of a combination of specific antibody and antigen (allergic reaction).
  • toxic products e.g. histamine, 5hydroxytryptamine, slow releasing substance (SRS-A), and others, which are produced as a result of a combination of specific antibody and antigen (allergic reaction).
  • the present invention in a second aspect'thus relates to a method useful for inhibiting the effects of the allergic reaction which comprises administering an effective amount of a compound selected from those represented by the following formulas:
  • R is hydrogen or lower alkyl; or a pharmaceutically acceptable non-toxic composition incorporating said acids, esters, amides or salts as an essential ingredient.
  • the compounds of the present invention are also smooth muscle relaxants, e.g. bronchial dilators, and are therefore useful in the treatment of conditions in which such agents may be indicated, as for instance in the treatment of bronchioconstriction.
  • the compounds of the present invention are also vasodilators and are therefore useful in the treatment of conditions in which such agents may be indicated, as for instance, in renal and cardiac disorders.
  • the present invention in a third aspect, is directed to pharmaceutical compositions useful for inhibitingthe effects of the allergic reaction comprising an effective amount of a compound selected from those represented by the following formulas:
  • esters, amides, and salts thereof wherein R is hydrogen or lower alkyl; in admixture with a pharmaceutically acceptable non-toxic carrier.
  • an effective amount of a compound of the present invention or pharmaceutical compositions thereof, as defined above is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or compounds of the present invention or other pharmaceutical agents, such as antibiotics, hormonal agents, and so forth.
  • These compounds or compositions can thus be administered orally, topically, parenterally, or by inhalation and in the form of either solid, liquid, or gaseous dosages including tablets, suspensions, and aerosols, as discussed in more detail hereinafter.
  • the administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum.
  • the method of the present invention is practiced when relief of symptoms is specifically required, or perhaps, imminent; however, the method hereof is also usefully practiced as continuous or prophylactic treatment.
  • the effective dosage in accordance herewith can vary over a wide range. Generally, an effective amount ranges from about 0.005 to about 100 mg. per kg. of body weight per day and preferably from about 0.01 to about 100 mg. per kg. of body Weight per day. In alternate terms, an effective amount in accordance herewith generally ranges from about 0.5 to about 7000 mg. per day per subject.
  • Useful pharmaceutical carriers for the preparation of the compositions hereof can be solids, liquids, or gases.
  • the compositions can take the form of tablets, pills, capsules, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like.
  • the carriers can be selected from the various oils including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium carbonate, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • Suitable pharmaceutical carriers and their formulation are described in Remingtons Pharmaceutical Sciences by E. W. Martin. Such compositions will, in any event, contain an effective amount of the active compound together with a. suitable amount of carrier so as to prepare the proper dosage form for proper administration to the host.
  • the compounds of the present invention demonstrate activity as inhibitors of the effects of the allergic reaction as measured by tests indicative of such activity involving passive cutaneous anaphylaxis as substantially described, for example, by J. Goose et al., Immunology, 16, 749 (1969).
  • the compounds of the present invention can be prepared in accordance with the following reaction sequence:
  • RO 200m (3) OOH COOH R'O R60 iJOOH (4) -oooan f oooa (RnzNo O oooru Rou h s coon n s l o 0 ll 1 00m ooon we ms wherein each of R R and R is lower alkyl, R and R being preferably methyl;
  • R is hydrogen or lower alkyl
  • halo is bromo, chloro, fluoro, or iodo, preferably bromo.
  • an ortho or para substituted (R phenol (2) is condensed with the 1,3-dicarbo(lower)alkoxy-4-halobenzene Compound 1 in the presence of cuprous oxide optionally in organic liquid reaction medium, preferably an organic amide such as dimethyl acetamide, dimethyl formamide, N-methylpyrrolidine, tetramethylurea, and so forth, to prepare the corresponding 1,3-dicarbo(lower)alkoxy-4-(oor p-substituted phenyloXy)-benzene Compound 3.
  • organic liquid reaction medium preferably an organic amide such as dimethyl acetamide, dimethyl formamide, N-methylpyrrolidine, tetramethylurea, and so forth, to prepare the corresponding 1,3-dicarbo(lower)alkoxy-4-(oor p-substituted phenyloXy)-benzene Compound 3.
  • the reaction is preferably conducted in an inert organic reaction medium, such as those listed above, or suitable mixtures of one or more of such medium.
  • the reaction is further conducted at temperatures ranging from about to about 220 C., preferably from about to 200 C., and for a period of time sufiicient to complete the reaction, ranging from about two hours to about 24 hours.
  • the reaction consumes the reactants on the basis of one mole of the substituted phenol per mole of the dicarbo- (lower)carboxyhalobenzene per half mole of cuprous oxide.
  • the amounts of the reactants to be em ployed are not critical, some of the desired Compound 3 product being obtained when employing any proportions thereof.
  • the reaction is conducted by reacting from about one to about three moles of the substituted phenol compound with about from one to about 1.2 moles and the dicarbo(lower) carboxyhalobenzene compound in the presence of from about 0.5 to about 0.6 mole of the cuprous oxide.
  • the inert organic reaction medium if employed, is used in solvent amounts.
  • the base hydrolysis conditions can be any employed conventionally in the art.
  • the hydrolysis reaction is conducted using an alkali metal hydroxide at about 50 to about 90 C. and for a period of time sufficient to complete the reaction, ranging from about 15 minutes to about 60 minutes, preferably in the presence of inert organic reaction media such as those normally employed in organic chemical reactions of this type, e.g., aqueous alkanol solutions.
  • inert organic reaction media such as those normally employed in organic chemical reactions of this type, e.g., aqueous alkanol solutions.
  • two moles of base are required per mole of Compound 3
  • the amounts employed are not critical to produce the desired hydrolysis.
  • Preferably from about three to about five moles of base are employed per mole of Compound 3 and the reaction media, if employed, is used in solvent amounts.
  • the thus prepared diacid Compound 4 is then cyclized with phosphoryl chloride, thionyl chloride, sulfuric acid, hydrogen fluoride, or, preferably, polyphosphoric acid '(PPA), to give the corresponding 5- or 7-substituted xanthone-Z-carboxylic acid Compound 5.
  • the reaction is preferably, but optionally, conducted in an inert organic reaction medium including those usually employed in organic chemical reactions, such as dimethylsulfoxide, sulfolane, benzene, toluene, and so forth.
  • the reaction is further conducted at temperatures ranging from about 60 to about 180 C., and for a period of time sufficient to complete the reaction ranging from about 15 minutes to about 90 minutes.
  • reaction consumes the reactants on the basis of one mole of Compound 4 per mole of cyclizing reagent
  • the reaction can be performed using any proportions of reactants. In the preferred embodiments, however, the reaction is conducted using from about 20 to about 50 moles of the cyclizing reagent per mole of starting Compound 4.
  • ethereal diazoalkane such as diazomethane and diazoethane or with the desired lower alkyl iodide in the presence of lithium carbonate at room temperature or with the desired lower alkanol in the presence of a trace of sulfuric acid at reflux.
  • the hydroxy acid esters (6) are then treated with a dialkylthiocarbamoyl chloride, such as dimethylthiocarbamoyl chloride, in the presence of base, such as an alkali metal hydride, and in organic liquid reaction media preferably an organic amide such as those listed above with respect to reaction (1+2- 3) to afford the products (7).
  • the reaction is conducted at temperatures ranging from about 20 to about 100 C., preferably from 60 to about 80 C. and for a period of time sufficient to complete the reaction, ranging from about 1 hour to about 6 hours. In the preferred embodiments, the reaction is conducted by reaction of from about 1.1 to about 1.5 moles of dialkylthiocarbamoyl chloride per mole of Compound 6.
  • the product Compounds 7 are then rearranged by reaction at a temperature of from about 200 to about 250 C., preferably from about 220 C. to about 230 C., and for a period of time ranging from about 1 hour to about 8 hours and in the presence of organic medium such as sulfolane, nitrobenzene, triethylene glycol and so forth, which is preferably employed in solvent amounts, to give Compound 8.
  • organic medium such as sulfolane, nitrobenzene, triethylene glycol and so forth, which is preferably employed in solvent amounts, to give Compound 8.
  • Compounds 8 are then converted to the corresponding 5- and 7-mercapto acid Compounds 9 by base hydrolysis such as those described above for the preparation of Compounds 4 from 3.
  • the 5- and 7-lower alkyl thio ether ester Compounds 10 are then prepared as described above (e.g., 5 6) or by reacting Compounds 9 with a lower alkyl halide in the presence of base such as potassium carbonate and organic liquid reactions medium such as those described above.
  • the reaction is conducted at a temperature ranging from about 20 to about C., preferably from 50 to about 60 C. and for a period of time sufficient to complete the reaction, ranging from about 2 hours to about 16 hours.
  • R is lower alkyl
  • an appropriate phenol (2) is treated with 1,3-dimethy1-4-halo-(preferably iodo) (14) J30 OH benzene (12) as described above, to prepare the corresponding 1,3-dimethyl-4-phenyloxybenzene (13).
  • This compound is then oxidized such as with potassium permanganate in aqueous t-butanol, to give the corresponding 1,3-dicarboxy-4-phenyloxybenzene (14).
  • This compound is then cyclized, as described above, to give the corresponding xanthone-Z-carboxylic acid (5) which can be treated as described above, to prepare the compounds of the present invention.
  • the acid esters of the xanthone-2-carboxylic acids hereof are prepared as described above (e.g., 5-) 6).
  • the amides of the xanthone-Z-carboxylic acids hereof are prepared by treatment of the acids with thionyl chlo-' ride followed by treatment with anhydrous ammonia or lower alkyl or dilower alkyl amine.
  • the salts of the xanthone-Z-carboxylic acids hereof are prepared by treating the corresponding acids with pharmaceutically acceptable base.
  • Representative salts derived from such pharmaceutically acceptable bases include the sodium, potassium, lithium, ammonia, calcium, magnesium, ferrous, ferric, zinc, manganous, aluminum, manganic, trimethylamine, triethylamine, tri-propylamine, (dimethylamino)ethanol, triethanolamine, B-(diethylamino)ethanol, arginine, lysine, histidine, N-ethylpiperidine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methyl glucamine, theobromine, purines, piperazine, piperidine, polyamine resins, caifeinc, procaine salts.
  • the reaction is conducted in an aqueous solution, alone or in combination with an inert, Water miscible organic solvent, at a temperature of from about C. to about 100 C., preferably at room temperature.
  • Typical inert, water miscible organic solvents include methanol, ethanol, isopropanol, butanol, acetone, dioxane, or tetrahydrofuran.
  • divalent metal salts such as the calcium salts or magnesium salts of the acids the free acid starting material is treated with about one molar equivalent of pharmaceutically acceptable base.
  • the aluminimum salts of the acids are prepared, about one molar equivalent of the pharmaceutically acceptable base are employed.
  • the calcium salts and magnesium salts of the acids are prepared by treating the corresponding sodium or potassium salts of the acids with at least one molar equivalent of calcium chloride or magnesium chloride, respectively, in an aqueous solution, alone or in combination with an inert water miscible organic solvent, at a temperature of from about 20 C. to about 100 C.
  • the aluminum salts of the acids are prepared by treating the acids with at least one molar equivalent of an aluminum alkoxide, such as aluminum triethoxide, aluminum tripropoxide and the like, in a hydrocarbon solvent, such as benzene, xylene, cyclohexane, and the like at a temperature of from 20 C. to about 115 C.
  • an aluminum alkoxide such as aluminum triethoxide, aluminum tripropoxide and the like
  • a hydrocarbon solvent such as benzene, xylene, cyclohexane, and the like
  • lower alkyl a lower alkyl group containing 1 to 5 carbon atoms including straight and branched chain groups and cyclic alkyl groups, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, t-butyl, n-pentyl, isopentyl, sec.-pentyl, t-pentyl, cyclopropyl, cyclobutyl and cyclopentyl.
  • lower alkoxy is intended the group O-lower alkyl" wherein lower alkyl is as defined above.
  • esters, amides, and salts are respectively intended a lower alkyl ester, lower alkyl being as defined above; an unsubstituted, mono(lower) alkyl, or (di)lower alkyl substituted amide, lower alkyl being as defined above; and a salt as defined above.
  • 1,3-dicarbomethoxy 4 (p-methoxyphenyloxy)-benzene (3 g.) is combined with 150 ml. of 5% potassium hydroxide in methanol. The resultant mixture is refluxed for 1 hour after which time it is acidified, cooled, and filtered, to give 1,3-dicarboxy-4-(p-methoxyphenyloxy)-benzene.
  • the foregoing procedure can be practiced using an alternative l,3-dicarboloweralkoxy-4-halo starting compound, such as 1,3-dicarbomethoxy-4-chloro- (or iodo) benzene, 1,3-dicarboethoxy-4-fluoro-benzene, 1,3-dicarboethoxy-4-bromobenzene, and the like, with similar results.
  • an alternate 4-lower alkoxyphenol starting compound to prepare the corresponding '7-lower alkoxyxanthone-2-carboxylic acids, e.g.
  • Example 9 The procedures of Example 1 are repeated using o-hydroxyphenol and p-hydroxyphenol as starting compounds to respectively prepare hydroxyxanthone-Z-carboxylic acid and 7-hydroxyzanthone-2-carboxylic acid.
  • the hydroxy compounds can be prepared from the lower alkoxy compounds of Example 1 according to the following representative procedure.
  • EXAMPLE 3 A mixture of 11 grams of 7-methoxyxanthone-2-carboxylic acid in 100 ml. of concentrated aqueous hydrogen iodide and 100 ml. of acetic acid is refluxed for 4 hours. After this time, the mixture is cooled, diluted with water, and filtered. The precipitate is washed and dried to give 7-hydroxyxanthone-Z-carboxylic acid.
  • EXAMPLE 4 A mixture of 4 grams of 7-hydroxyxanthone-2-carboxylic acid, g. of methyl iodide, and 10 g. of lithium carbonate in 50 ml. of dimethylformamide is stirred at room temperature for a period of 16 hours. After this period of time, the reaction mixture is poured into dilute hydrochloric acid-ice and the resultant mixture extracted with ethyl acetate. The extracts are filtered through alumina to give methyl 7 hydroxyxanthone-Z-carboxylate which can be recrystallized from methanol.
  • Methyl 7-dimethylthiocarbamoyloxyxanthone-Z-carboxylate ((8 g.) in 150 ml. of sulfolane is stirred at 230C. under nitrogen. After a total of 6 hours under these conditions, t.l.c. indicates the absence of starting material. The mixture is cooled to 80 C. and 150 ml. of hot water are slowly added. The mixture is then cooled and the filtered solid washed with water and dried to give methyl 7-(dimethylcarbamoylthio)xanthone-Z-carboxylate.
  • Methyl 7-(dimethylcarbarnoylthio)-xanthone-2-carboxylate (7.5 g.), 10 g. of potassium hydroxide and 250 ml. of 80% aqueous ethanol is refluxed for 1 hour. After this time, 250 ml. of Water are added and the mixture is treated wtih charcoal, filtered, acidified. The product is filtered oif and dried to give 7-mercaptoxanthone-2-carboxylic acid.
  • 5-mercaptoxanthone-2-carboxylic acid is prepared from methyl S-hydoxyxanthone-2-carboxylate.
  • EXAMPLE 6 A mixture of 3 g. of 7-mercaptoxanthone-2-carboxylic acid in 150 ml. of dimethylformamide, 5 ml. of methyl iodide and 5 ml. of potassium carbonate is stirred for 16 hours at 60 C. The mixture is then poured into dilute hydrochloric acid and the resultant mixture extracted with ethyl acetate. The extracts are chromatographed on alumina (methylene chloride) to give methyl 7-(methylthio)-xanthone-2-carboxylate (i.e. methyl 7-thiomethoxyxanthone-Z-carboxylate) which can be recrystallized from methylene chloride/ methanol.
  • alumina methylene chloride
  • a mixture of 0.8 g. of 7-mercaptoxanthone-2-carboxylic acid, 2 ml. of 2-bromopropane, and excess potassium carbonate in 50 ml. of dimethylformamide is stirred for 24 hours at 75 C.
  • Dilute hydrochloric acid and ethanol are added, the solid filtered off and washed.
  • the solid is saponified with sodium carbonate in aqueous methanol (30 minutes reflux).
  • the alkaline solution is diluted with water, treated with charcoal, filtered, and acidified to give 7-(isopropylthio)-xanthone-2-carboxylic acid which can be recrystallized from tetrahydrofuran/ethyl acetate.
  • EXAMPLE 7 A mixture of 51.5 g. of 1,3-dimethyl-4-iodobenzene (4- iodo-m-xylene), 40 g. of p-methoxyphenol, 16 g. of cuprous oxide in 300 ml. of dimethylacetamide is heated to the boiling point and maintained under reflux (190 C.) for 144 hours with stirring and under a nitrogen atmosphere. The reaction mixture is then poured into ice water and extracted with ether and the extracts are filtered through 500 g. of alumina in hexane to give 1,3-dimethyl 4- p-methoxyphenyloxy) -benzene.
  • a mixture of 41 g. of 1,3-dimethyl-4-(p-methoxyphenyloxy)-benzene, 300 g. of potassium permanganate, 500 ml. of t-butanol, and 750 ml. of water is heated to the boiling point and maintained thereat for a period of 3 hours. After distilling ofi the t-butanol, the reaction mixture is filtered, the clear filtrate acidified and the precipitate of 1,3 dicarboxyl-4-(p-methoxyphenyloxy)-benzene is isolated by suction filtration and washed with water.
  • the 1,3 dicarboxy-4-(p-methoxyphenyloxy) benzene thus prepared is then cyclized as described in Example 1 or 8 hereof to give 7-methoxyxanthone-2-carboxylic acid which can be converted to 7-hydroxyxanthone-Z-carboxylic acid.
  • EXAMPLE 8 A mixture of 1,3-dimethyl-4-bromobenzene, 10.5 g. of o-methoxyphenol, 4.65 g. of cuprous oxide, 40 ml. of tetramethylurea, and 75 ml. of N-methylpyrrolidone is stirred at for 96 hours. The resultant mixture is diluted with water and extracted with methylene chloride. The methylene chloride extracts are chromatographed on 300 g. of alumina with gradient elution using hexanezether to give 1,3 dimethyl-4-(o-methoxyphenyloxy) -benzene.
  • a mixture of 12 g. of 1,3-dimethyl-4-(o-methoxyphenyloxy)-benzene, 72 g. of potassium permanganate, 200 ml. of t-butanol and 350 ml. of water is refluxed for 4 /2 hours. After this time, the t-butanol is distilled off, and the reaction mixture is filtered. The filtrate is acidified to give 1,3-dicarboxy 4 (o-methoxyphenyloxy) benzene which can be recrystallized from benzenezheptane.
  • a mixture of 3 g. of 1,3-dicarboxy-4-(o-methoxyphenyloxy)-benzene, 75 ml. of polyphosphoric acid, and 75 ml. of sulfol-ane is stirred at 125 C. for a period of 2 hours. After this time, the reaction mixture is poured into water, filtered and the precipitate washed. The precipitate is recrystallized from acetic acid (charcoal) to give S-methoxyxanthone-Z-carboxylic acid which can be converted to 5-hydroxyxanthone-2-carboxylic acid.
  • EXAMPLE 9 A mixture of 4.5 g. of 7-(methylthio)-xanthone-2-carboxylic acid, 10 g. of methyl iodide, and 10 g. of lithium carbonate in 75 ml. of dimethylformamide is stirred at room temperature for a period of 18 hours. After this period of time, the reaction mixture is poured into dilute hydrochloric acid-ice and the resultant precipitate is filtered off and washed to give methyl 7-(meth ylthio)- xanthone-Z-carboxylate.
  • the other xanthone-Z-carboxylic acids hereof containing substituents at the C5 or C7 positions, prepared as described above, can be converted to the corresponding acid esters, e.g. ethyl 7-mercaptoxanthone-2-carboxylate (by use of one equivalent of lithium carbonate), ethyl S-(methylthio)-xanthone-2-carboxylate, methyl 7-(isopropylthio)-xanthone-2-carboxylate, methyl S-(isopropylthio)-xanthone-2-carboxylate, ethyl 7-(isopropylthio)-xanthone-2-carboxylate, ethyl S-(isopropylthio)-xanthone 2-carboxylate, and so forth.
  • acid esters e.g. ethyl 7-mercaptoxanthone-2-carboxylate (by use of one equivalent of lithium
  • the potassium and lithium salts are prepared.
  • an appropriate metal salt reagent e.g. calcium chloride, manganese chloride, and so forth
  • the other xanthone-Z- carboxylic acid salts are prepared, e.g.
  • magnesium 7- methylthio)-xanthone-2carboxylate calcium 7-(methylthio)-xanthone-2-carboxylate, aluminum 7-(methylthio)- xanthone-Z-carboxylate, ferrous 7- (methylthio)-xanthone- 2-carboxylate, zinc 7-(methylthio)-xanthone-2-carboxylate, manganese 7-(methylthio)-xanthone 2-carboxylate, ferric 7-(methylthio)-xanthone-2-carboxylate, and so forth.
  • the xanthone-Z-carboxylic acid salts of the other C-S or C7 substituted xanthone-Z- carboxylic acids hereof are prepared, e.g. potassium 5- mercaptoxanthone-Z-carboxylate, sodium 7-(isopropylthio)-xanthone-2-carboxylate, sodium 5-(isopropy1thio)- xanthone-Z-carboxylate, and so forth.
  • EXAMPLE 1 1 To a mixture of 50 ml. of concentrated aqueous ammonia in 500 ml. of methanol there are added 20 g. of 7- (ethylthio)-xanthone-2-carboxylic acid. The resultant mixture is stirred for 2 hours and is then evaporated to dryness to give the ammonium salt of 7-(ethylthio)-xanthonc-2- carboxylic acid.
  • a solution of 10 g. of 7-ethylthioxanthone-Z-carboxylic acid in 50 ml. of thionyl chloride is heated at reflux for one hour. Thereafter, the solution is evaporated to dryness to give the corresponding acid chloride to which is added a concentrated ethereal ammonia solution. The resultant solution is evaporated giving 7-(ethylthio)-xanthone-2- carboxylic acid amide.
  • the lower alkyl amides can be prepared using monoalkylamine or dialkylamine in lieu of ammonia in the above procedures.
  • prepared e.g. are 7- (methylthio)-xanthone-2-carboxylic acid amide, N-methyl 7(n-propylthio)-xanthone-2-carboxylic acid amide, N,N- dimethyl 5(methylthio)-xanthone 2 carboxylic acid amide, N,N-diethy1 7-(ethylthio)-xanthone-2Pcarboxylic acid amide, N-ethyl 7-mercaptoxanthone-Z-carboxylic acid amide, N-n-propyl 7-(isopropylthio)-xanthone-2- carboxylic acid amide, and so forth.
  • EXAMPLE 12 To a mixture of 20 g. of procaine and 500' ml. of aqueous methanol are added 20 g. of 7-(methylthio)-xanthone- Z-carboxylic acid. The resultant mixture is stirred at room temperature for 16 hours. It is then evaporated under reduced pressure, to give the procaine salt of 7-(methylthio)-xanthone-2-carboxylic acid.
  • the lysine, caffeine, and arginine salts thereof are obtained.
  • the e.g. procaine, lysine, caffeine, and arginine salts of the other 5- and 7-substituted xanthone-Z-carboxylic acids are obtained, e.g.
  • EXAMPLE 14 The following procedure illustrates a test procedure for the compounds hereof.
  • Inhibition of reaginic antigen-antibody reactions in rats is regarded as representative of inhibition of human reaginic allergic episodes.
  • Subjects challenged by antigen inhalation are measured for the extent of provoked degree of asthma condition by changes in airway resistance on expiration.
  • the subject compounds are administered as an aerosol by inhalation before antigen challenge.
  • Prevention of asthmatic conditions upon the administration of the compounds is evidenced by a decrease in airway resistance and other, subjective improvements, e.g. reduced cough.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US00174259A 1971-08-23 1971-08-23 Substituted xanthone carboxylic acid compounds Expired - Lifetime US3803174A (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
US00174259A US3803174A (en) 1971-08-23 1971-08-23 Substituted xanthone carboxylic acid compounds
ES404787A ES404787A1 (es) 1971-08-23 1972-07-12 Un procedimiento para la preparacion de nuevos compuestos de acidos xantonacarboxilicos sustituidos.
CH1030676A CH592076A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-23 1972-07-12
DE19722265051 DE2265051A1 (de) 1971-08-23 1972-07-12 Neue substituierte xanthoncarbonsaeureamide
DE2234250A DE2234250A1 (de) 1971-08-23 1972-07-12 Neue substituierte xanthoncarbonsaeureverbindungen
GB3253272A GB1398097A (en) 1971-08-23 1972-07-12 Substituted xanthone carboxylic acid compounds
JP6984472A JPS5344473B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-23 1972-07-12
NL7209619A NL7209619A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-23 1972-07-12
SE7209195A SE387945B (sv) 1971-08-23 1972-07-12 Sett att framstella c-5- och c-7-merkapto- och legre-alkyltiosubstituerade xanton-2-karbonsyraforeningar
CA146,892A CA1012543A (en) 1971-08-23 1972-07-12 Substituted xanthone carboxylic acid compounds
FR7225355A FR2150309B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-23 1972-07-12
CH1045572A CH591470A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-08-23 1972-07-12
US425885A US3885038A (en) 1971-08-23 1973-12-18 Method of using substituted xanthone carboxylic acid
ES435560A ES435560A1 (es) 1971-08-23 1975-03-12 Un procedimiento para la preparacion de nuevos compuestos de acidos xantona-carboxilicos sustituidos.
ES435561A ES435561A1 (es) 1971-08-23 1975-03-12 Un procedimiento para la preparacion de nuevos compuestos de acidos xantona-carboxilicos sustituidos.
HK308/76*UA HK30876A (en) 1971-08-23 1976-05-27 Novel substituted xanthone carboxylic acid compounds
MY134/76A MY7600134A (en) 1971-08-23 1976-12-30 Novel substituted xanthone carboxylic acid compounds
JP4631577A JPS537675A (en) 1971-08-23 1977-04-21 Production of xantonecarboxylic acid derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00174259A US3803174A (en) 1971-08-23 1971-08-23 Substituted xanthone carboxylic acid compounds

Publications (1)

Publication Number Publication Date
US3803174A true US3803174A (en) 1974-04-09

Family

ID=22635483

Family Applications (1)

Application Number Title Priority Date Filing Date
US00174259A Expired - Lifetime US3803174A (en) 1971-08-23 1971-08-23 Substituted xanthone carboxylic acid compounds

Country Status (12)

Country Link
US (1) US3803174A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS5344473B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1012543A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH592076A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE2234250A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES404787A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2150309B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1398097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK30876A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY7600134A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7209619A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE387945B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47519A (en) * 1974-07-09 1979-03-12 Roussel Uclaf 7-sulphinimidoyl(sulphimidoyl)-xanthone-2-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
JPS5746820U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1980-08-29 1982-03-16

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications

Also Published As

Publication number Publication date
CH591470A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-09-15
ES404787A1 (es) 1975-11-16
GB1398097A (en) 1975-06-18
FR2150309B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-11-21
FR2150309A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-04-06
CA1012543A (en) 1977-06-21
HK30876A (en) 1976-06-04
JPS537675A (en) 1978-01-24
JPS4829779A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-04-19
MY7600134A (en) 1976-12-31
SE387945B (sv) 1976-09-20
JPS5344473B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-11-29
CH592076A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-10-14
ES435561A1 (es) 1976-12-16
DE2234250A1 (de) 1973-03-01
NL7209619A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-02-27
ES435560A1 (es) 1976-12-16
DE2265051A1 (de) 1976-02-19

Similar Documents

Publication Publication Date Title
US3885038A (en) Method of using substituted xanthone carboxylic acid
US3864493A (en) Compositions and methods for the prevention of asthmatic symptoms
US4816487A (en) 1-(2-hydroxyaryl)-alkane-1-on-oximes-procedure of preparation and use in pharmaceuticals
US3484445A (en) Derivatives of chromone-2-carboxylic acid
US3427324A (en) Derivatives of chromone-2-carboxylic acid
US3686320A (en) Bis-phenoxy compounds
US3952013A (en) 1-Thiachromone-2-carboxylic acids and derivatives
US3801598A (en) Substituted xanthone carboxylic acid compounds
US3803174A (en) Substituted xanthone carboxylic acid compounds
US3849565A (en) Disubstituted xanthone carboxylic acid compounds for inhibiting asthma
US3904647A (en) Thioxanthone carboxylic acids and derivatives
US3835167A (en) Anthrone carboxylic acids and derivatives
US3821251A (en) Disubstituted xanthone carboxylic acid compounds
EP0243071B1 (en) Di-t-butylphenols substituted by a thenoyl group
US3835157A (en) Heterocyclic substituted xanthone carboxylic acid compounds
US3835139A (en) N-substituted acridone carboxylic acids and derivatives
US3818042A (en) Xanthone carboxylic acids and derivatives
US3886181A (en) Disubstituted xanthone carboxylic acid compounds
US3859442A (en) A method of inhibiting symptoms of asthma
US3951618A (en) Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds
US3819654A (en) Unsaturated ether substituted xanthone carboxylic acid compounds
US3835158A (en) Heterocyclic substituted xanthone carboxylic acid compounds
US3949084A (en) Novel substituted xanthone carboxylic acid compounds
US3867407A (en) Substituted xanthone carboxylic acid compounds
US3886162A (en) Acridone carboxylic acids and derivatives